Literature DB >> 19150569

Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis.

Jonathan L Wright1, James Hotaling, Michael P Porter.   

Abstract

PURPOSE: Upper tract tumors occur in 2% to 7% of patients after primary bladder cancer, making surveillance upper tract imaging part of bladder cancer management. We determined the cumulative incidence of secondary upper tract tumor development after primary bladder cancer and risk factors for secondary upper tract tumors using contemporary population based data.
MATERIALS AND METHODS: We identified patients with bladder cancer in the Surveillance, Epidemiology, and End Results cancer registry from 1988 to 2003. All subsequent cases of upper tract tumors were ascertained. Multivariate Cox survival analysis was performed to evaluate risk factors for secondary upper tract tumors after adjusting for age, race, gender, stage, grade, tumor location, surgical management, year of diagnosis and tumor registry.
RESULTS: Of 99,338 patients with bladder cancer upper tract tumors developed in 768 (0.8%). The median time to secondary upper tract tumors was 33 months. Of upper tract tumors 71% developed within 5 years of bladder cancer diagnosis and only 6% developed more than 10 years after diagnosis. On multivariate analysis high grade (HR 2.16, 95% CI 1.71-2.74) and nonmuscle invasive disease (Ta, T1) (HR 1.16, 95% CI 0.97-1.39) were predictive of upper tract tumor recurrence. Upper tract disease was more likely to develop in patients with tumors at the trigone/ureteral orifice (HR 1.76, 95% CI 1.48-2.09).
CONCLUSIONS: Upper tract tumors developed in 0.8% of patients with bladder cancer. Although late cases occurred, upper tract tumors developed in the majority of cases within 3 years. Pathological factors such as tumor grade, stage and location were predictive of upper tract recurrence. These findings may be useful for tailoring surveillance protocols in patients with bladder cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19150569     DOI: 10.1016/j.juro.2008.10.168

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols.

Authors:  Nathan Perlis; Polat Turker; Peter J Bostrom; Cynthia Kuk; Tuomas Mirtti; Girish Kulkarni; Neil E Fleshner; Michael A S Jewett; Antonio Finelli; Alexandre R Zlotta
Journal:  World J Urol       Date:  2012-07-19       Impact factor: 4.226

2.  Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study.

Authors:  Philipp Nuhn; Giacomo Novara; Christian Seitz; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Thomas J Walton; Hans-Martin Fritsche; Stefan Tritschler; Juan I Martínez-Salamanca; Vincenzo Ficarra; Pierre I Karakiewicz; Guido Mazzoleni; Shahrokh F Shariat; Patrick J Bastian
Journal:  World J Urol       Date:  2014-07-22       Impact factor: 4.226

3.  Prognostic values of distal ureter involvement and survival outcomes in bladder cancer at T1 and T2 stages: a propensity score matching study.

Authors:  Song Xiao; Xiangpeng Zhan; Tao Chen; Jingxin Wu; Linhao Xu; Ming Jiang; Wen Deng; Ke Zhu; Zhenhao Zeng; Xiaofeng Cheng; Qiang Zhou; Wei Huang; Xiaochen Zhou; Cheng Zhang; Bin Fu; Gongxian Wang
Journal:  Int Urol Nephrol       Date:  2022-08-13       Impact factor: 2.266

Review 4.  [Renal pelvic carcinoma: a different urothelial tumor?].

Authors:  F Hofstädter
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

5.  Monitoring of the upper urinary tract in patients with bladder cancer.

Authors:  Rajinikanth Ayyathurai; Mark S Soloway
Journal:  Indian J Urol       Date:  2011-04

6.  Risk factors for upper tract urothelial recurrence following local excision of bladder cancer.

Authors:  Ning Lin; Yu-Peng Wu; Yun-Zhi Lin; Xuan Tao; Shao-Hao Chen; Zhi-Bin Ke; Yong Wei; Qing-Shui Zheng; Xue-Yi Xue; Ning Xu
Journal:  Cancer Med       Date:  2018-06-28       Impact factor: 4.452

7.  Stratifying risk for multiple, recurrent, and large (≥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer.

Authors:  Jungyo Suh; Jae Hyun Jung; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Investig Clin Urol       Date:  2021-07

Review 8.  Nephron-sparing management of upper tract urothelial carcinoma.

Authors:  Jason M Farrow; Sean Q Kern; Gustavo M Gryzinski; Chandru P Sundaram
Journal:  Investig Clin Urol       Date:  2021-07

Review 9.  Oncologic outcomes of radical nephroureterectomy (RNU).

Authors:  Alexander P Kenigsberg; Xiaosong Meng; Rashed Ghandour; Vitaly Margulis
Journal:  Transl Androl Urol       Date:  2020-08

10.  Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer.

Authors:  Marie C Hupe; Lukas Dormayer; Tomasz Ozimek; Julian P Struck; Martin J P Hennig; Melanie Klee; Christoph A J von Klot; Markus A Kuczyk; Axel S Merseburger; Mario W Kramer
Journal:  BMC Cancer       Date:  2020-02-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.